Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis

Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis

Sorafenib resistance is often developed and impedes the benefits of clinical therapy in hepatocellular carcinoma (HCC) patients. However, the relationship between sorafenib resistance and tumor immune environment and adjuvant drugs for sorafenib-resistant HCC are not systemically identified. This st...

Full description

Bibliographic Details
Main Authors: Zhi-Yong Liu, Dan-Ying Zhang, Xia-Hui Lin, Jia-Lei Sun, Weinire Abuduwaili, Guang-Cong Zhang, Ru-Chen Xu, Fu Wang, Xiang-Nan Yu, Xuan Shi, Bin Deng, Ling Dong, Shu-Qiang Weng, Ji-Min Zhu, Xi-Zhong Shen, Tao-Tao Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Pharmacology
Subjects:
immune gene signature
sorafenib resistance
tumor immune microenvironment
adjuvant drugs
bioinformatics analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.952482/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.952482/full

Similar Items